On Target Laboratories, Inc.
Developer of targeted intraoperative molecular imaging agents that use receptor-targeted small molecules conjugated to near-infrared dyes to make cancerous tissue visible to surgeons during operations. The company advances these agents through preclinical development, Phase 1–3 clinical trials, regulatory submissions, commercialization and post-market real-world evidence generation, with programs focused on lung, ovarian and other metastatic cancers.
Industries
Nr. of Employees
small (1-50)
On Target Laboratories, Inc.
West Lafayette, Indiana, United States
Patents
Methods of manufacture and synthesis of fluorescent dye compounds and uses thereof
US-12673940-B2
View DetailsSynthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
US-12144874-B2
View DetailsCompositions including pafolacianine for the identification of malignant lesions
US-11986540-B2
View DetailsMethods of manufacture and synthesis of fluorescent dye compounds and uses thereof
US-11964965-B2
View Details
Methods of manufacture and synthesis of fluorescent dye compounds and uses thereof
US-12673940-B2
View DetailsSynthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
US-12144874-B2
View DetailsCompositions including pafolacianine for the identification of malignant lesions
US-11986540-B2
View DetailsMethods of manufacture and synthesis of fluorescent dye compounds and uses thereof
US-11964965-B2
View DetailsProducts
Folate receptor-targeted near-infrared fluorescent imaging agent (intravenous injectable)
An intravenously administered, receptor-targeted small-molecule conjugated to a near-infrared dye designed to accumulate in cancer cells and provide real-time fluorescent visualization of malignant and certain non-malignant lesions during surgery.
Folate receptor-targeted near-infrared fluorescent imaging agent (intravenous injectable)
An intravenously administered, receptor-targeted small-molecule conjugated to a near-infrared dye designed to accumulate in cancer cells and provide real-time fluorescent visualization of malignant and certain non-malignant lesions during surgery.
Services
Operational support and regulatory submission assistance to provide investigational imaging agents to eligible patients under an open IND when clinical trial enrollment is not possible.
Site enablement, investigator training on agent administration and imaging workflows, and operational support during Phase 2/3 studies and post-market studies.
Engagement with payers and health systems to secure procedure coding and payment pathways for intraoperative imaging use, including support for NTAP and procedure code adoption.
Operational support and regulatory submission assistance to provide investigational imaging agents to eligible patients under an open IND when clinical trial enrollment is not possible.
Site enablement, investigator training on agent administration and imaging workflows, and operational support during Phase 2/3 studies and post-market studies.
Engagement with payers and health systems to secure procedure coding and payment pathways for intraoperative imaging use, including support for NTAP and procedure code adoption.
Expertise Areas
- Intraoperative molecular imaging
- Targeted small-molecule imaging agent development
- Clinical trial design and execution (Phase 1–3)
- Real-world evidence generation and clinical publications
Key Technologies
- Near-infrared fluorescence imaging
- Folate receptor-targeted ligand chemistry
- Small-molecule–dye conjugation
- Intravenous injectable formulation for intraoperative use
News & Updates
Recognized in Fast Company’s list of the World’s Most Innovative Companies, ranked #5 in the Medicines, Therapeutics, and Pharmaceuticals category.
Announcement that more than 1,000 surgeries have used the company’s intraoperative imaging agent since commercialization.
Recognition for the company’s intraoperative imaging agent in the Best in Biz awards for healthcare and medical innovation.
Initial FDA approval for intraoperative identification of ovarian cancer and a subsequent supplemental approval for detection in the lung.
Published real-world study showing high nodule localization rate and translation of clinical-trial findings into clinical practice.
Phase 3 clinical trial results demonstrating intraoperative localization of occult pulmonary malignancy.
Recognized in Fast Company’s list of the World’s Most Innovative Companies, ranked #5 in the Medicines, Therapeutics, and Pharmaceuticals category.
Announcement that more than 1,000 surgeries have used the company’s intraoperative imaging agent since commercialization.
Recognition for the company’s intraoperative imaging agent in the Best in Biz awards for healthcare and medical innovation.
Initial FDA approval for intraoperative identification of ovarian cancer and a subsequent supplemental approval for detection in the lung.
Published real-world study showing high nodule localization rate and translation of clinical-trial findings into clinical practice.
Phase 3 clinical trial results demonstrating intraoperative localization of occult pulmonary malignancy.